Molecular Otolaryngology and Renal Research Laboratories |

Featured Content

Uncontrolled complement activity drives many diseases including two ultra-rare renal diseases. MORL provides a metric to follow a patient’s clinical course. MORL Clinical Testing Menu
Providing the most accurate clinically-driven interpretation of genetic variants in a timely manner MORL Clinical Diagnostic Services
The Molecular Otolaryngology and Renal Research Laboratories (MORL) is a CLIA approved, Joint Commission accredited diagnostic laboratory with a technical expertise in clinical genetic testing and interpretation. MORL Certifications and Licensure
What does it mean to get your testing done at the MORL? Testing at MORL
Working to increase our knowledge base of non-syndromic hearing loss and complement-mediated renal disease, including the development of new treatment options for both hearing loss, aHUS and C3G. Research at MORL


Ordering Genetic Hearing Loss Testing	Ordering Genetic Renal Panel Testing	Ordering Complement Functional Testing
OtoSCOPE provides comprehensive genetic testing for all genes implicated in non-syndromic hearing loss and many types of syndromic hearing loss. An Usher Syndrome Panel is also available. 1/4/2021: OtoSCOPE v9 - same outstanding translational clinical medicine supported by visionary informatics and dedicated staff...now with more genes.	Genetic Renal Panel screens patients diagnosed with thrombotic microangiopathies and C3 glomerulopathy. The next-generation sequencing panel includes analysis of 12 genes for single nucleotide variants as well as MLPA, which identifies copy-number variations in the CFH-CFHR5 genomic region.	Comprehensive complement testing includes quantitating complement proteins and their cleavage products, measuring complement activity, and screening for autoantibodies.

Your results are discussed at a multidisciplinary meeting.
Your testing is performed in the Clinical Division of the MORL by scientists who lead the world in the human genetics of deafness and complement-mediated renal diseases.
Our testing is the most comprehensive clinical testing available.

16th DDD/C3G Family Conference:
October 16, 2021 - Virtual Conference